U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

FOROPAFANT

MORE DETAILS

  VWJ2QVH41J

Status:
Investigational
Source:
INN:foropafant
Source URL:
https://tripod.nih.gov/npc/#Download
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Platelet-activating factor receptor
3
Conditions:
Thrombosis
22
Acute asthma
2
Ulcerative colitis
125
Foropafant is a platelet-activating factor (PAF) antagonist which was developed by Sanofi. It was in clinical development for the treatment of asthma, thrombosis and ulcerative colitis. The development of the drug was discontinued due to lack of efficacy.

FOROPAFANT FUMARATE

MORE DETAILS

  77229931IM

Status:
Investigational
Source:
INN:foropafant
Source URL:
https://tripod.nih.gov/npc/#Download
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Platelet-activating factor receptor
3
Conditions:
Thrombosis
22
Acute asthma
2
Ulcerative colitis
125
Foropafant is a platelet-activating factor (PAF) antagonist which was developed by Sanofi. It was in clinical development for the treatment of asthma, thrombosis and ulcerative colitis. The development of the drug was discontinued due to lack of efficacy.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966